CRDF vs CBAT Comparison

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

CBAK Energy Technology Ltd is a high-tech enterprise in China engaged in the development, manufacturing, and sales of new-energy high-power lithium-ion and sodium-ion batteries, as well as the production of raw materials for high-power lithium batteries. The Company's products and solutions are used in electric vehicles, light electric vehicles, energy storage systems, and other high-power applications.